Towards an optimized in-vitro SPR assay for antibody Fcg receptor binding kinetics
|
|
- Magdalene Sims
- 6 years ago
- Views:
Transcription
1 Towards an optimized in-vitro SPR assay for antibody Fcg receptor binding kinetics Åsa Frostell 1, Robert Karlsson 1, Jerrard Hayes 2, Matilda Lindgren 1, Pauline Rudd 2, and Cecilia Annerén 1 1 GE Healthcare Bio-Sciences AB, Rapsgatan 23, SE Uppsala, Sweden 2 National Institute for Bioprocessing, Research and Training, Dublin, Ireland First published in Sep 2012 at BEBPA, Lisbon, Portugal
2 Introduction Therapeutic antibodies are now approved for a number of different indications. One important antibody (Ab) attribute is its Fc effector function, and Abs are now being engineered with the aim of obtaining desired binding of the Ab Fc region to Fc receptors (FcR) on immune effector cells. Optimized and standardized FcR assays may impact the understanding of the function FcR-Ab interactions. They can be used through all stages of antibody development, process development and QC; they may also play an important role in comparability studies and for the evaluation of biosimilars. 2
3 Introduction The use of Biacore as a biochemical assay for studies of FcR Ab Fc binding is already established in this area; however there is a lack of consensus regarding assay set up and evaluation of the often complex binding kinetics. Examples of published assay setups include amine coupling of FcR (1), anti-his capture of His tagged FcR (2), amine coupling of Ab (3), Protein A capture of Ab (4), anti-kappa F(ab )2 capture of Ab (5), anti-fab capture of Ab (6). In the present study, assay setups and kinetic evaluations using Biacore T200 are discussed. Results using commercially available, recombinant extracellular FcgRs from two different expression systems, HEK293 (Sino Biological) and NS0 cells (R&D Systems), are presented. 3
4 Kinetics depend on assay setup Rituximab binding to Fcg receptors After feasibility studies of most of the published Biacore assay setups, we focused on and compared two formats, with the aim of finding a setup suitable for screening of Ab - FcgR binding. Protein A capture of Ab was compared more closely with anti-his mab capture of His-tagged FcR. 4
5 Kinetics depend on assay setup Significant differences in kinetic data were found upon visual comparison of sensorgrams, depending on whether the FcR or the Ab was immobilized. 5
6 His-tag FcγR capture method Therap. Ab FcR Anti-His Assay condition details: Sensor chip CM5 with 6000 to RU amine coupled anti-his mab (from His Capture Kit) in active and ref. flow cell Running buffer: PBS-P+ Capture: μg/ml His-tagged FcR, 60 s injection, 5 μl/min in active flow cell Capture stabilization time, 1 3 min, added for some FcRs. Capture levels for these FcRs: RU Single cycle kinetics (2-5 injections) over active and reference flow cell nm Ab conc. series for FcγRI, nm for FcγRIIIa. 60 s injection at 30 μl/min. Regeneration: 10 mm Glycine, ph 1.5, 30 s Blank cycles (FcR capture + buffer injections) performed first, last and upon change of FcR + The product (Ab) is in solution, retaining full flexibility + Avoiding Protein A and possible risk of Ab binding also with Fab part + Ab is more often than FcR available in the high concentrations needed to measure week interactions + Oriented capture of His tagged FcR. Neutral buffer for immobilization. + Single cycle kinetics consumes low amounts of FcR + His capture kit adds convenience. Easy switch of different FcRs and Abs. - Need to know Ab concentration 6
7 Specific capture of FcR His-tagged Fcγ receptors binding to immobilized anti-his Ab (blue bar) compared to binding to dextran and to immobilized irrelevant Abs. All IgG1. Specific binding of FcγRs to the anti-his Ab was obtained. Binding to irrelevant Abs were negligible (< 7% of binding to anti-his). 7
8 FcgRIIIa Two state model 8
9 FcgRI Heterogeneous ligand model 9
10 Antibody binding to Fcγ receptors from different cell lines 10
11 IgG3, with different glycosylation patterns, binding to FcγRIIIa Binding kinetics for IgG3 binding to FcγRIIIa F158 (HEK) Glycosylation analysis of IgG3 by UHPLC. Significant kinetic differences betwee the IgG3 preparations IgG3, Sigma: heterogenous collection N-glycans; minor sialylation (11.5%) and extensive core fucosylation (91% IgG3, The Binding Site and Millipore: very different glycan profiles, albeit identical to each other. Higher levels of sialylation, monosialylated structures in 19.5% of glycans, di-sialylated in 1.5%. Core fucosylatio in only 23% of glycans. Differences in e.g. core fucosylation could possibly be used to explain the binding differences, a phenomenon previously reported for IgG1 binding to FcγRIIIa*. *Lifely et al. Glycobiol, Shields et al, J Biol Chem, Shinkawa et al, J Biol Chem 2003, and others. 11
12 Conclusions An His FcR capture assay was found suitable for antibody-fcgr binding studies. Antibodies exhibited complex binding to both FcgRI and FcgRIIIa receptors. Binding data indicated different binding mechanisms to FcgRI and FcgRIIIa respectively. Binding to FcgRI could be modeled as two independent reactions, while binding to FcgRIIIa could be modeled by assuming two states of the reaction. Significant differences in binding to FcgRIIIa were observed for IgG3 preparations with differences in glycosylation pattern. 12
13 References 1. Bruhns P., et al. Blood, 2009, 113, Shibata-Koyama M., et al. Glycobiology, 2009, 19, Hatayama K., et al. Appl Microbiol Biotechnol, 2012, 94, Heider K., et al. Blood, 2011, 118, Ha S., et al. Glycobiology, 2011, 21, Ferrara C., et al. PNAS, 2011, 108, Starovasnik M., et al. Protein Science, 1999, 8, Royle L., et al. Methods Mol Biol. 2006, 347, Ferrara C., et al. Biotech Bioeng, 2006, 93,
14 Acknowledgment 2013 General Electric Company - All rights reserved. GE, imagination at work, and GE monogram are trademarks of General Electric Company. Biacore is a trademark of GE Healthcare companies. All goods and services are sold subjects to the terms and conditions of sale of the company within GE Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information. First published Sep
Biacore comparability tool for quantitating binding similarities in IgG Fcγ receptor analysis
GE Healthcare Biacore comparability tool for quantitating binding similarities in IgG Fcγ receptor analysis Assessment and control of Fc functionality during biotherapeutic antibody development and manufacturing
More informationLabel-free interaction analysis in realtime using surface plasmon resonance
GE Healthcare Technology Note 23 Biacore systems Label-free interaction analysis in realtime using surface plasmon resonance Providing quantitative data on: report point Specificity sensorgram To what
More informationPerformance of a fast Surface Plasmon Resonance based MAb quantification method
Performance of a fast Surface Plasmon Resonance based MAb quantification method T. Björkman, E. Monié and T. Eriksson GE Healthcare Bio-Sciences AB, R&D, Björkgatan 30, SE-751 84 Uppsala, Sweden First
More informationAC Immune SA, Lausanne, Switzerland *For correspondence:
Binding Affinity Measurement of Antibodies from Crude Hybridoma Samples by SPR Dorin Mlaki Ndao, David T. Hickman, María Pilar López-Deber, Aurélien Davranche, Andrea Pfeifer and Andreas Muhs * AC Immune
More informationGE Healthcare Life Sciences. A year of interaction with Biacore X100
GE Healthcare Life Sciences A year of interaction with Biacore X1 Protein interaction research Real-time monitoring of binding events using surface plasmon resonance (SPR) gives a deep understanding of
More informationImplementation of the Next Generation Effector Function Assays for Comparability Assessments
Implementation of the Next Generation Effector Function Assays for Comparability Assessments March 25, 2014 Poonam Aggarwal Bioassays 2014: Scientific Approaches & Regulatory Strategies to be held March
More informationBiosensing Probe for Quality Control Monitoring of the Structural Integrity of Therapeutic Antibodies
Supporting Information Biosensing Probe for Quality Control Monitoring of the Structural Integrity of Therapeutic Antibodies Hideki Watanabe, Seiki Yageta, Hiroshi Imamura, and Shinya Honda *,, Biomedical
More informationValidation of a concentration assay using Biacore C
GE Healthcare Application Note 48 Biacore systems Validation of a concentration assay using Biacore C Guideline for development of a GxP - compliant concentration assay Support for informed decision-making
More informationSURFACE PLASMON RESONANCE-BASED SYSTEMS
SURFACE PLASMON RESONANCE-BASED SYSTEMS ADVANCED METHODS IN BIOENGINEERING LABORATORY 3/1/2011 1 Schedule Week 1: Introduction Reagents preparation Ligand immobilization of Protocol 1 Week 2: Kinetics
More informationInstruction AB
GE Healthcare Life Sciences Instruction 28-9242-34 AB Biacore Biotin CAPture Kit Product description Order code: Contents: Storage: Kit capacity: 28-9202-33 (Biotin CAPture Kit) 28-9202-34 (Biotin CAPture
More informationPurification of lambda Fab Characterization of a new affinity chromatography resin
Characterization of a new affinity Linus Laurin, Maria Ersoy and Pia Thunman GE Healthcare Bio-Sciences AB, Uppsala, Sweden First presented at the Next Generation Protein Therapeutics Summit, in San Francisco,
More informationBiacore X100. GE Healthcare Life Sciences. Biacore X100 Plus Package. Biacore X100 delivers:
GE Healthcare Life Sciences Data file 28-9592-29 AB Biacore label-free interaction analysis Biacore X100 Biacore X100 (Fig 1) is an automated and versatile system for comprehensive, label-free analysis
More informationProteOn XPR36 Quantikinetics: Antibody Concentration and Detailed Kinetic Analysis in a Single Experimental Cycle
ProteOn XPR36 Quantikinetics: Antibody Concentration and Detailed Kinetic Analysis in a Single Experimental Cycle Gary Ross, Mingde Zhu, Ruben Luo, Bio-Rad Laboratories, Inc., 2 Alfred Nobel Drive, Hercules,
More informationProfiling inhibitor selectivity for PARP protein family members
GE Healthcare Application note -979-1 AA Biacore label-free interaction analysis Profiling inhibitor selectivity for PARP protein family members Inhibitors of PARP1, a member of the family of human poly-adp-ribose
More informationProtein-peptide Interaction by Surface Plasmon Resonance Eiji Ishii, Yoko Eguchi and Ryutaro Utsumi *
Protein-peptide Interaction by Surface Plasmon Resonance Eiji Ishii, Yoko Eguchi and Ryutaro Utsumi * Bioscience Department, Kinki University, Nara, Japan *For correspondence: utsumi@nara.kindai.ac.jp
More informationCharacterization of drug-plasma protein interactions using surface plasmon resonance
GE Healthcare Characterization of drug-plasma protein interactions using surface plasmon resonance Binding to plasma proteins is a key parameter in evaluating candidate compounds during the lead optimization
More informationRegeneration Scouting Kit
GE Healthcare Life Sciences Instruction 22-0618-29 AC Biacore Regeneration Scouting Kit Product description Order code: Contents: Storage: Safety: BR-1005-56 Ethylene glycol (p.a.), 11 ml Glycine-HCl,
More informationIn Vitro Glycoengineering - Its Application and Effect on IgG1
In Vitro Glycoengineering - Its Application and Effect on IgG1 Glycobiology Conference, 2015 AAPS National Biotechnology Conference, June 8-10, 2015, San Francisco Dietmar Reusch, Marco Thomann, Development
More informationQualifying SPR immunogenicity assays Dr. Christian Kühne
Qualifying SPR immunogenicity assays Dr. Christian Kühne Bioagilytix / IPM Biotech global CRO for large molecule bioanalysis supporting pre-clinical & clinical studies Biomarker, Pharmacokinetics, Immunogenicity
More informationReducing Non-Specific Binding in Surface Plasmon Resonance Experiments
1 Reducing Non-Specific Binding in Surface Plasmon Resonance Experiments SUMMARY Reducing non-specific binding (NSB) is essential to generating accurate data with SPR The effect of bovine serum albumin,
More informationGE Biacore T Check that the waste bottle is empty.
GE Biacore T200 General Care and Maintenance The instrument should be left ON at all times, and in Standby Mode. Report problems immediately in the booking system: https://ppms.us/hms-cmi. Refer to the
More informationSupplementary Figure 1. Binding capacity of the nanoparticles. Protein A-coated magnetic nanoparticles were mixed with FITC-antibody (antibody
Supplementary Figure 1. Binding capacity of the nanoparticles. Protein A-coated magnetic nanoparticles were mixed with FITC-antibody (antibody conjugated with FITC) and PE-antibody (antibody conjugated
More informationTarget-based drug discovery and lowbinding affinities using Biacore 8K
Target-based drug discovery and lowbinding affinities using Biacore 8K GE Healthcare October 2016 Imagination at work Drug discovery trends Fragment-based approaches widely established Moving towards new
More informationPhenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy Supplementary Materials SUPPLEMENTARY MATERIALS
More informationSelection guide Biacore consumables
Selection guide Biacore consumables No matter what you want to get out of your interaction analysis, GE Healthcare has developed a range of tools designed specifically to make Biacore assays as easy and
More informationprotein interaction analysis tech note 5540
protein interaction analysis tech note 55 Screening, Ranking, and Epitope Mapping of Anti-Human IL-9 Supernatants Tsafrir Bravman, 1 Vered Bronner, 1 Daniel Laune, 2 Nicolas Novali, 2 Dominique Piquer,
More informationprotein interaction analysis
protein interaction analysis protocol guide 5821 Guide to Ligand Immobilization on the ProteOn XPR36 System Laura Moriarty, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel Drive, Hercules, CA 94547 USA.
More informationEnhance Your Protein Interaction Research with A New Level of Bench-Top Productivity
LAMDAGEN C O R P O R A T I O N Enhance your research with real-time monitoring and quantitation of biomolecular binding with highly sensitive detection in a label-free format 9 Enhance Your Protein Interaction
More informationThe World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc.
The World Leader in SPR Technology Jimmy Page, PhD, Biacore, Inc. Objectives of Biacore Experiments Yes/No Data» Is there binding?» Ligand Fishing Concentration Analysis: How MUCH? Active Concentration
More informationShort half-life of human IgG3 due to competition for FcRn-mediated
Short half-life of human due to competition for FcRn-mediated transport reveals its therapeutic potential. Nigel M. Stapleton 1, Jan Terje Andersen 2,3#, Annette M. Stemerding 4#, Stefania P. Bjarnarson
More informationGE Healthcare Life Sciences. Biacore systems. Confidence that comes with the right interactions
GE Healthcare Life Sciences Biacore systems Confidence that comes with the right interactions Confidence that comes with the right interactions Biacore systems from GE Healthcare Life Sciences Label-free
More informationBasic Biacore Course. Introduction to SPR technology. Biacore Training
Basic Biacore Course Introduction to SPR technology What Biacore measure Biomolecular Interactions Specificity Kinetics How Specific... How Fast & How Strong... Affinity Concentration Thermodynamics How
More informationMethods to Determine the Binding of Bevacizumab to Fc receptors
DATASHEET Methods to Determine the Binding of Bevacizumab to Fc receptors BACKGROUND Bevacizumab (Avastin ) is a humanized recombinant monoclonal antibody that inhibits angiogenesis by binding to the vascular
More informationHis Buffer Kit is intended for research use only, and should not be used in any clinical or in vitro procedures for diagnostic purposes.
GE Healthcare Instructions 28-4010-39 AC His Buffer Kit Intended use His Buffer Kit is intended for research use only, and should not be used in any clinical or in vitro procedures for diagnostic purposes.
More informationLigand immobilization using thiol-disulphide exchange
A P P L I C A T I T E 9 Ligand immobilization using thiol-disulphide exchange Abstract This Application ote describes an immobilization procedure based on thioldisulphide exchange, providing a valuable
More informationMolecular Interactions Research
Molecular Interactions Research Group (MIRG) Satya P. Yadav, Aaron P. Yamniuk, John Newitt, Michael L. Doyle, Ed Eisenstein, Thomas A. Neubert Presented at: ABRF 2013 (RG9 session), Palm Springs, CA March
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationStrategies to Improve Drug Tolerance in Nab Assays
Strategies to Improve Drug Tolerance in Nab Assays Steven J Swanson, PhD Senior Vice President, Research ImmunoCellular Therapeutics Ltd steven.swanson@imuc.com AAPS National Biotech Conference June 2015
More informationFast, precise, and accurate
B i op r o c e s s Technical Development and Qualification of a Generic IgG Quantification Assay Using Surface Plasmon Resonance Stefan Winheim, Anton Walser, and Matthias Kania Fast, precise, and accurate
More informationSeparation of Native Monoclonal Antibodies and Identification of Charge Variants:
Separation of Native Monoclonal Antibodies and Identification of Charge Variants: Teamwork of the Agilent 31 OFFGEL Fractionator, Agilent 21 Bioanalyzer and Agilent LC/MS Systems Application Note Biosimilar
More informationBIAffinity Application Note
BIAffinity Application Note Rifs analysis of the interaction between antibody mab1 and mab1 binding peptide pep1 1 Introduction The BIAffinity used in these studies is based on the detection principle
More informationPolishing of monoclonal antibodies in bind/elute mode using Capto MMC ImpRes
Polishing of monoclonal antibodies in bind/elute mode using Capto MMC ImpRes Bengt Westerlund, Kristina Nilsson-Välimaa, Anders Ljunglöf, Peter Hagwall and Patrik Adielsson GE Healthcare Bio-Sciences AB,
More informationSurface Plasmon Resonance Analysis of Antigen-Antibody Interaction Mitsuhiro Nishimura and Kazuyoshi Ikuta *
Surface Plasmon Resonance Analysis of Antigen-Antibody Interaction Mitsuhiro Nishimura and Kazuyoshi Ikuta * Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka,
More informationBiacore 8K. One solution for small molecule and biotherapeutic screening/characterization. GE Healthcare. Label-free interaction analysis
GE Healthcare Label-free interaction analysis Biacore 8K Biacore 8K efficiently delivers binding data with the quality you expect, meeting your toughest challenges in small molecule and biotherapeutic
More informationReflected light a b. prism. flow chamber. flow chamber
GE Biacore T200 Getting Started Guide Introduction The Biacore T200 is an instrument for Surface Plasmon Resonance (SPR), an optical technique that measures changes in refractive index near a metal surface
More informationAntibody-Mediated Effector Function: Learning and Challenges from Early Discovery to Development
Antibody-Mediated Effector Function: Learning and Challenges from Early Discovery to Development Payal Mehta, PhD Research Scientist Eli Lilly & Company CaSSS Bioassay Conference, Silver Spring, MD 9 th
More informationBIA Experimental Designs
s What are the Basics? Immobilization Binding Interactions Regenerations Controls 1 BIA Terminologies Ligand : Bound component Analyte: Flow-through component BIA Terminologies Resonance Units: Units used
More informationExpectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective
Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective Christian Mayer AGES - Austrian Agency for Health and Food Safety Analytical Technologies Europe
More informationAccurate comparability assessment of a biosimilar interferon in process development
Application note 9-1154-78 AC Protein analysis Accurate comparability assessment of a biosimilar interferon in process development This application note describes how to achieve accurate comparability
More informationConvenient Purification of Monoclonal Antibodies using HiTrap rprotein A FF
GE Healthcare Convenient Purification of Monoclonal Antibodies using HiTrap rprotein A FF M. Carlsson, A. Heijbel, and A-C. Häggqvist GE Healthcare AB, Björkgatan 3, SE-751 84 Uppsala, Sweden Abstract
More informationBiochemical Binding ADCC Assays Utilizing AlphaLISA Toolbox Reagents for the Characterization of higgs and FcγR1A
APPLICATION NOTE AlphaLISA Technology Authors: Daniel Cardillo Stephen Hurt PerkinElmer, Inc. Hopkinton, MA Biochemical Binding ADCC Assays Utilizing AlphaLISA Toolbox Reagents for the Characterization
More informationLabel-Enhanced SPR Improves the Detectability of Label-Free Surface Plasmon Resonance Analysis 100x
episentec Label-Enhanced SPR Improves the Detectability of Label-Free Surface Plasmon Resonance Analysis 1x Anders Hanning, Episentec Drug Discovery 15, Telford, 2-3 September 215 Episentec - Better Biosensors
More informationFunctional Role of Glycosylation in a Human IgG 4 Antibody Assessed by Surface Plasmon Resonance Technology
The Open Pharmacology Journal, 212, 6, 27-33 27 Open Access Functional Role of Glycosylation in a Human IgG 4 Antibody Assessed by Surface Plasmon Resonance Technology Rosie B. Wong 1, Ming Zeng 1, An-Horng
More informationBiochemical Binding ADCC Assays Utilizing LANCE Toolbox Reagents for the Characterization of higgs and FcγR1A
APPLICATION NOTE LANCE TR-FRET Author: Daniel Cardillo PerkinElmer, Inc. Hopkinton, MA Biochemical Binding ADCC Assays Utilizing LANCE Toolbox Reagents for the Characterization of higgs and FcγR1A Introduction
More informationGE Healthcare. Biacore X100. Getting Started
GE Healthcare Biacore X100 Getting Started 2 Biacore X100 Getting Started 28-9615-81 Edition AA Contents Contents Biacore X100 Getting Started Introduction... 5 Requirements...5 References...5 Contents
More informationFabRICATOR-HPLC is an HPLC column for fast on-column digestion of monoclonal antibodies.
Genovis / Products / IgG Proteases / FabRICATOR / FabRICATOR-HPLC Products Detailed Information Key Characteristics How to Order Documents FAQ & Support Patent & Disclaimer Applications FabRICATOR -HPLC
More informationApplication of Biacore Technology
Principles and typical results Application of Biacore Technology Common types of Biacore analyses Specificity analysis Is my molecule of interest specific for its target? Multiple binding analysis In which
More informationUniversity of Colorado Denver, Biophysics Core Facility August 2008
1 I. Introduction. The majority of this tutorial is derived from the Biacore manual, Getting Started BIACORE 3000. This tutorial is designed to acquaint the user with the basic operating principles and
More informationLabel-free interaction analysis Biacore 8K and Biacore 8K+
Label-free interaction analysis Biacore 8K and Biacore 8K+ Biacore 8K and Biacore 8K+ systems efficiently deliver binding data of outstanding quality, meeting your toughest challenges in screening, characterization,
More informationThe Ludger GX-mAb Glycoprofiling Service High Throughput glycan analysis service of monoclonal antibodies (mabs) for drug developers and manufacturers
The Ludger GX-mAb Glycoprofiling Service High Throughput glycan analysis service of monoclonal antibodies (mabs) for drug developers and manufacturers Dr Richard Gardner Senior Chemist richard.gardner@ludger.com
More informationMabSelect SuRe pcc. Medium characteristics. GE Healthcare. Affinity chromatography. Optimized for continuous chromatography applications
GE Healthcare Affinity chromatography MabSelect SuRe pcc MabSelect SuRe pcc affinity chromatography medium (resin) offers exceptional capacity at short residence time, making it well-suited for applications
More informationEfficient and controlled expansion of IgG1 producing CHO-DG44 cells using the ActiCHO Media System and WAVE Bioreactor
Efficient and controlled expansion of IgG1 producing CHO-DG44 cells using the ActiCHO Media System and WAVE Bioreactor Thomas Falkman, Eric Fäldt, Anita Vitina and Cecilia Annerén. GE Healthcare Bio-Sciences
More informationAlbumin & IgG Depletion SpinTrap
GE Healthcare Albumin & IgG Depletion SpinTrap Albumin & IgG Depletion SpinTrap is designed for depletion of albumin and IgG from human plasma or serum. Product booklet Code: 28-9480-20 Page finder 1.
More informationCharacterizing lead compounds using label-free interaction analysis: Blocking T-cell activation in rheumatoid arthritis therapy
G Healthcare pplication note 28-9383-78 Label-free interaction analysis haracterizing lead compounds using label-free interaction analysis: locking T-cell activation in rheumatoid arthritis therapy locking
More informationADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies
ADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies Richard Somberg, Ph.D. October 2012 Outline Introduction to ADCC Problem with classic
More informationUnderstanding Mechanisms of Action and Structure Function Relationships: A Regulator s Perspective
Understanding Mechanisms of Action and Structure Function Relationships: A Regulator s Perspective Marjorie Shapiro, Ph.D. Office of Biotechnology Products/CDER Bioassays 2018 April 17, 2018 Disclaimer
More informationAVB Sepharose High Performance
GE Healthcare Life Sciences Data file 28-927-54 AB Custom designed media AVB Sepharose High Performance AVB Sepharose High Performance is an affinity chromatography medium (resin) designed for the purification
More informationFast Trak Services: a collaborative project to accelerate downstream biosimilar process development
GE Healthcare Fast Trak Services: a collaborative project to accelerate downstream biosimilar process development A case study Case study, 2924332 AA Fast Trak Services A collaborative project to accelerate
More informationCapture of human single-chain Fv (scfv) fusion protein on Capto L affinity medium
GE Healthcare Life Sciences Application note 29-0144-56 AA Affinity chromatography Capture of human single-chain Fv (scfv) fusion protein on Capto L affinity medium We describe the capture of a single-chain
More informationGLYCOENGINEERING FOR THERAPEUTIC PROTEINS. Technical Journal Club, 15 th July Sandra Ivic
GLYCOENGINEERING FOR THERAPEUTIC PROTEINS Technical Journal Club, 15 th July 2014 Sandra Ivic MAMMALIAN GYLCAN BIOSYNTHETIC PATHWAY Consensus sequence for N- Glycans: N-X-S/T No consensus sequence found
More informationSupplementary Figure 1.
9 8 5 6F12 IgG2a Isotype Control 5 1 15 Supplementary Figure 1. Passive treatment with isotype control mab does not affect viral challenge. Wild type mice were treated with 4 mg/kg of mouse IgG2a 6F12
More informationCapacity and performance of MabSelect PrismA protein A chromatography resin
Capacity and performance of protein A chromatography resin is a protein A resin of which both the ligand and the base matrix have been optimized. The resin exhibits improved capacity over its predecessor
More informationPurification of alpha-1 antitrypsin using an antibody based affinity chromatography medium
Purification of alpha-1 antitrypsin using an antibody based affinity chromatography medium Ulrika Meyer a, Hanna Wlad a, Sven Blokland b, Frank J.M. Detmers b and Henrik Ihre a a GE Healthcare Bio-Sciences
More informationAssessment of process performance and product quality in high-performing fedbatch
Assessment of process performance and product quality in high-performing fedbatch Thomas Falkman, Anita Vitina, Annika Morrison, Tomas Björkman, and Andreas Castan GE Healthcare Life Sciences, Björkgatan
More informationBiphasic cultivation strategy for optimized protein expression and product quality
Biphasic cultivation strategy for optimized protein expression and product quality Christian Kaisermayer 1, Andreas Gili 2, Robert Weik 3 1 GE Healthcare Life Sciences, Björkgatan 30, 75184 Uppsala, Sweden.
More informationGE Healthcare Life Sciences. Label-free interaction and stability analysis in vaccine design and development
GE Healthcare Life Sciences Label-free interaction and stability analysis in vaccine design and development Analytical tools for modern vaccines The growing public awareness of a potential pandemic, requiring
More informationStreptavidin Mag Sepharose
GE Healthcare Life Sciences Data file 28-9921-05 AB Protein sample preparation Streptavidin Mag Sepharose Streptavidin Mag Sepharose (Fig 1) is a magnetic bead for simple and efficient enrichment of target
More informationHiTrap NHS-activated HP
GE Healthcare Life Sciences Instructions 71-7006-00 AW HiTrap affinity columns HiTrap NHS-activated HP 1 ml and 5 ml HiTrap NHS-activated HP is a prepacked ready to use, column for preparative affinity
More informationData Sheet. TCR activator / PD-L1 - CHO Recombinant Cell line Cat. #: 60536
Data Sheet TCR activator / PD-L1 - CHO Recombinant Cell line Cat. #: 60536 Product Description Recombinant CHO-K1 cells constitutively expressing human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274, B7
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationIdentification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy
Identification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy Ziping Wei, Ph.D. Analytical Biochemistry MedImmune January 25, 2010 Outline Why do we need to identify
More informationGE Healthcare Life Sciences. Getting the best out of your Biacore system
GE Healthcare Life Sciences Getting the best out of your Biacore system A flying start No matter what you want to get out of your interaction analysis, GE Healthcare has developed a range of tools designed
More informationAssays and Strategies for Immunogenicity Assessment. Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen
Assays and Strategies for Immunogenicity Assessment Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen General Antibody Assay Strategy Correlation of clinical findings
More informationDiscovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A
Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A Contacts: Marty Simonetti martysimonetti@gmail.com Kirby Alton kirby.alton@abeomecorp.com Rick Shimkets
More informationPurification strategies and platform alternatives for monoclonal antibodies
Purification strategies and platform alternatives for monoclonal antibodies Annika Forss, Anna Grönberg, Anders Ljunglöf, Karin Torstenson GE Healthcare Life Sciences, Björkgatan 30, SE-751 84 Uppsala,
More informationPotelligent CHOK1SV. How It Works. Potelligent CHOK1SV
Potelligent CHOK1SV Potelligent CHOK1SV Potelligent CHOK1SV How It Works A new host cell line for the production of recombinant antibodies has been developed through close collaboration between Lonza and
More informationprotein interaction analysis tech note 5367
protein interaction analysis tech note 5367 Rapid Optimization of Immobilization and Binding Conditions for Kinetic Analysis of Protein-Protein Interactions Using the ProteOn XPR36 Protein Interaction
More informationPhage Antibody Selection With Reichert SPR System
Phage Antibody Selection With Reichert SPR System Reichert Technologies Webinar April 4, 2016 Mark A. Sullivan, Ph.D. Department of Microbiology and Immunology University of Rochester Presentation Outline
More informationAb SpinTrap Ab Buffer Kit
GE Healthcare Data File 28-9020-30 AB Protein Sample Preparation Ab SpinTrap Ab Buffer Kit The Ab SpinTrap and the Protein G HP SpinTrap are identical columns. The difference between the article numbers
More informationImprovement of Aptamer Affinity by Dimerization
Sensors 2008, 8, 1090-1098 sensors ISSN 1424-8220 2008 by MDPI www.mdpi.org/sensors Full Research Paper Improvement of Aptamer Affinity by Dimerization Hijiri Hasegawa, Ken-ichi Taira, Koji Sode and Kazunori
More informationSuppl. Table I. Design of mutations within the BIIB4 and BIIB5 scfvs for screening in a thermal challenge assay.
Suppl. Table I. Design of mutations within the and scfvs for screening in a thermal challenge assay. scfv position (Kabat numbering) Residue Frequency a Covariation DEEK or Rosetta c scfv position (Kabat
More informationImproving biosensor analysis
JOURNAL OF MOLECULAR RECOGNITION J. Mol. Recognit. 1999;12:279 284 Improving biosensor analysis David G. Myszka* Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA The quality
More informationBiosimilars China Guideline. Dr Dr Michel Mikhail
Biosimilars China Guideline Dr Dr Michel Mikhail 1 Contents Regulatory context of biologicals in China Decree 28 issued by SFDA October 2007 Proposed biosimilars guideline 10/29/14 Reference drugs to use
More informationData Sheet PD-1 / NFAT - Reporter - Jurkat Recombinant Cell Line Catalog #: 60535
Data Sheet PD-1 / NFAT - Reporter - Jurkat Recombinant Cell Line Catalog #: 60535 Product Description Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements
More informationBiopharmaceuticals - Current FDA & EMAs Regulations on glycan analysis
Biopharmaceuticals - Current FDA & EMAs Regulations on glycan analysis Jayesh Kattla, PhD March 2015 Gothenburg & Copenhagen 2013 Waters Corporation 1 Hope and Risk 2013 Waters Corporation 2 The total
More informationSupplementary methods
Supplementary methods Cell culture, infection, transfection, and RNA interference HEK293 cells and its derivatives were grown in DMEM supplemented with 10% FBS. Various constructs were introduced into
More informationQuality of biologicals
Quality of biologicals K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Typical biotech manufacturing
More informationSolvent Correction versus In-line Reference Measurement
Technical Note Solvent Correction versus In-line Reference Measurement Optical systems such as SPR and BLI often have difficulty with nonspecific noise when measuring low molecular weight analyte in organic
More informationReducing Cycle Time for Charge Variant Analysis of Monoclonal Antibodies
Reducing Cycle Time for Charge Variant Analysis of Monoclonal Antibodies Alternating Column Regeneration Using an Agilent 1200 Infinity Series Quick-Change Bio-inert 2-position/10 port Valve Application
More informationphab Amine and Thiol Reactive Dyes for Antibody Internalization Studies Nidhi Nath, Ph.D. Group Leader, Protein Analysis Promega Corporation
phab Amine and Thiol Reactive Dyes for Antibody Internalization Studies Nidhi Nath, Ph.D. Group Leader, Protein Analysis 1 Outline 1. phab Dyes 2. Protocols for conjugating phab Dyes to antibodies 3. Applications:
More information